"Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France (RIME)"

PHASE4CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2011

Conditions
Opioid Dependency
Interventions
DRUG

Buprenorphine (Subutex)

Sublingual tablet

DRUG

Buprenorphine/naloxone (Suboxone)

Sublingual tablet

Trial Locations (20)

Unknown

Csst Antibes, Antibes

Hopital Paul Guiraud, Bagneux

Cssa Bizia, Bayonne

Centre Carreire , CH Charles Perrens, Bordeaux

CHU de Clermont-Ferrand, Centre Méthadone, Clermont-Ferrand

Service d'addictologie, Hopital de Dole, Dole

CSST NAUTILIA (Ex Alinea), Le Havre

CSST Le Cèdre Bleu, Lille

Centre Hospitalier Esquirol - Intersecteur, Regional Soins en Addictologie, Limoges

Centre Baudelaire, Metz

Csst de Montauban, Montauban

CSST Centre Hospitalier, Nice

CSST Logos, Nîmes

Hôpital Caremeau, Nîmes

Csst Espace Murger, Paris

Hôpital Saint Anne, Paris

Centre L'Envol (Csst), Rennes

Centre Baudelaire, Thionville

Hopital Joseph Ducuing, Toulouse

CSST Centre Port Bretagne CH Charles Perrens, Tours

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Indivior Inc.

INDUSTRY

NCT00955162 - "Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France (RIME)" | Biotech Hunter | Biotech Hunter